Cellular resistance to anthracyclines

General Pharmacology

Volumn 27, Issue 2, 1996, Pages 251-255

  Nielsen, Dorte ^a   Maare, Christian ^b   Skovsgaard, Torben ^b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b NONE

Author keywords

antineoplastic agents; drug resistance

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; DAUNORUBICIN; DNA; DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; GLUTATHIONE; GLUTATHIONE TRANSFERASE; GLYCOPROTEIN P; VERAPAMIL;

ANTINEOPLASTIC ACTIVITY; CELL MEMBRANE; DETOXIFICATION; DNA METABOLISM; DNA REPAIR; DRUG DISTRIBUTION; DRUG MECHANISM; DRUG RESISTANCE; GENETIC TRANSCRIPTION; HUMAN; MULTIDRUG RESISTANCE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; TUMOR CELL;

EID: 0029921888     PISSN: 03063623     EISSN: None     Source Type: Journal    
DOI: 10.1016/0306-3623(95)02013-6     Document Type: Article

References (30)

1. Bankusli I., Yin M., Mazzoni A., Abdellah A. and Rustum Y. M. (1989) Enhancement of adriamycin-induced cytotoxicity by increasing retention and inhibition of DNA repair in DOX-resistant P388 cell lines with the new calcium blocker DMDP. Anticancer Res. 9, 567-574.
2. Booser D. J. and Hortobagyi G. N. (1994) Anthracycline antibiotics in cancer therapy. Focus on drug resistance. Drugs 47, 223-258.
3. Chen C. J., Chin J. E. Ueda K, Clark D. P., Pastan I., Gottesman M. M. and Roninson I. B. (1986) Internal duplication and homology with bacterial transport proteins in the mdr 1 (P-glycoprotein) gene from multidrug-resistant human cells. Cell 47, 381-389.
4. Chen Y.-N., Mickley L. A., Schwartz A. M., Acton E. M., Hwang J. and Fojo A. (1990) Characterization of adriamycin-resistant human breast cancer cells which display overexpression of a novel resistance-related membrane protein. J. Biol Chem. 265, 10073-10080.
5. Cole S. P. C., Bhardwaj G. , Gerlach J. H., Mackie J. E., Grant C. E., Almquist K. C., Stewart A. J., Kurz E. V., Duncan A. M. V. and Deeley R. G. (1992) Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 258, 1650-1653.
6. Coley H. M., Amos W. B., Twentyman P. R. and Workman P. (1993) Examination by laser scanning confocal fluorescence imaging microscopy of the subcellular localisation of anthracyclines in parent and multidrug resistant cell lines. Br. J. Cancer 67, 1316-1323.
7. Cunnings J., Anderson L., Willmont N. and Smyth J. F. (1991) The molecular pharmacology of doxorubicin in vivo. Eur. J. Cancer 27, 532-535.
8. Danø K. (1973) Active outward transport of daunomycin in resistant Ehrlich ascites tumor cells. Biochem. Biophys. Acta. 323 466-483.
9. Deffie A. M., McPherson J. P., Gupta R. S., Hedley D. W. and Goldenberg G. J. (1992) Multifactorial resistance to antineoplastic agents in drug-resistant P388 murine leukemia, Chinese hamster ovary, and human HeLa cells, with emphasis on the role of DNA topoisomerase II. Biochem. Cell Biol. 70, 354-364.
10. Endicott J. A. and Ling V. (1989) The biochemistry of P-glycoprotein-mediated multidrug resistance. Annu. Rev. Biochem. 58, 137-171.
11. Ford J. M. and Hait W. N. (1990) Pharmacology of drugs that alter multidrug resistance in cancer. Pharmoc. Rev. 42, 155-199.
12. Friedberg E. C. (1985) DNA Repair. Freeman, New York.
13. Friche E., Danks M. K., Schmidt C. A. and Beck W. T. (1991) Decreased DNA topoisomerase II in daunorubicin-resistant Ehrlich ascites tumor cells. Cancer Res. 51, 4213-4218.
14. Galski H., Sullivan M., Willingham M. C., Chin K.-V., Gottesman M. M., Pastan I. and Merlino G. T. (1989) Expression of a human resistance cDNA (MDR1) in the bone marrow of transgenic mice: resistance to daunomycin-induced leukopenia. Mol. Cell Biol. 9, 4357-4363.
15. Gottesman M. M. and Pastan I. (1993) Biochemistry of multidrug resistance mediated by the multidrug transporter. Ann. Rev. Biochem. 62, 385-427.
16. Higgins C. F. (1992) ABC transporters: from microorganism to man. Annu. Rev. Cell Biol. 8, 67-113.
17. Krishnamachary N. and Center M. S. (1993) The MRP gene associated with a non P-glycoprotein multidrug resistance encodes a 190-kDa membrane bound glycoprotein. Cancer Res. 53, 3658-3661.
18. List A. F. (1995) Preclinical investigations of drug resistance. Curr. Opin. Oncol. 7, 19-27.
19. Nielsen D., Maare C., Poulsen F., Lauridsen S. T. and Skovsgaard T. (1994a) The relationship between resistance, P-glycoprotein content, and steady state accumulation in five series of Ehrlich ascites tumor cell lines selected for resistance to daunorubicin. Cell. Pharmac. 1, 127-135.
20. Nielsen D., Maare C., Skovsgaard T. (1994b) Kinetics of daunorubicin transport in Ehrlich ascites tumor cells with different expression of P-glycoprotein. Influence of verapamil. Biochem. Pharmac. 47, 2125-2135.
21. Osheroff N., Zechiedrich E. L. and Gale K. C. (1991) Catalytic function of DNA topoisomerase II. BioEssays 13, 269-275.
22. Raderer M. and Scheithauer W. (1993) Clinical trials of agents that reverse multidrug resistance. A literature review. Cancer 72, 3553-3563.
23. Raviv Y., Pollard H. B., Bruggemann E. P., Pastan I. and Gottesman M. M. (1990) Photosensitized labeling of a functional multidrug transporter in living drug-resistant tumor cells. J. Biol. Chem. 265, 3975-3980.
24. Roninson I. G. (1992) From amplication to function: the case of the MDR1 gene. Mutat. Res. 276, 151-161.
25. r 110,000 vesicular protein in non-P-glycoprotein-mediated resistance. Cancer Res. 53, 1475-1479.
26. Shuurhuis G. J., Broxterman H. J., Cervantes A.,van Heijningen T. H. M., de Lange J. H. M., Baak J. P. A. Pinedo H. M. and Lankelma J. (1989) Quantitative determination of factors contributing to doxorubicin resistance in multidrug-resistant cells. J. Natl. Cancer Inst. 81, 1887-1892.
27. Skovsgaard T., Nielsen D., Maare C. and Wassermann K. (1994) Cellular resistance to cancer chemotherapy. International Review of Cytology. A Survey of Cell Biology (Edited by Jeon K. W. and Jarvik J.), pp. 77-157. Academic Press, San Diego.
28. Sullivan D.M. and Ross W. E. (1991) Resistance to inhibition of DNA topoisomerases. In Molecular and Clinical Advances in Anticancer Drug Resistance (Edited by Ozols R. F.), pp. 57-99. Kluwer, Boston.
29. Tew K.D. (1994). Glutathione-associated enzymes in anticancer drug resistance. Cancer Res. 54, 4313-4320.
30. Versantvoort C. H. M., Broxterman H. J., Pinedo H. M., de Vries E. G. E., Feller N., Kuiper C. M. and Lankelma J. (1992) Energy-dependent processes involved in reduced drug accumulation in multidrug-resistant human lung cancer cell lines without P-glycoprotein expression. Cancer Res. 52, 17-23.